Elevated intraocular pressure (IOP) is a causative risk factor for the development and progression of glaucoma. Several new pathogenic pathways have been identified that cause primary open-angle glaucoma. Glaucomatous mutations in Myocilin (MYOC) damage the trabecular meshwork and elevate IOP in humans and in mice. Aqueous humor levels of the pro-fibrotic cytokine TGF?2 are elevated in POAG patients, and TGF?2 elevates IOP in perfusion cultured anterior segments and in rodent eyes. Animal models of glaucoma are important to discover and better understand molecular pathogenic pathways and test new glaucoma therapeutics. Although a number of different animal models of glaucoma have been developed and characterized, there are no true models of human POAG. Our overall hypothesis is that using human POAG relevant transgene (i.e. mutant MYOC and TGF?2) expression in mouse eyes to elevate IOP will cause glaucomatous optic neuropathy and retinopathy in mice. The following two specific aims will address and test this hypothesis: (SA#1) We will conduct a limited mouse strain survey to identify a mouse strain(s) with MYOC- or TGF?2-induced ocular hypertension that develops glaucomatous optic neuropathy and retinopathy. (SA#2) Once we have identified a sensitive strain, we will further characterize glaucomatous damage in this strain by assessing optic nerve and RGC damage and testing visual functions over time (0-12 weeks). The development of a relevant mouse model of human POAG will allow the molecular dissection of pathogenic pathways using the power of mouse genetics as well as provide an important new model for assessing new therapeutic approaches for the treatment of glaucoma.

Public Health Relevance

Glaucoma is a leading cause of irreversible visual impairment and blindness in the United States. Elevated eye pressure damages tissues in the back of the eye. This study will develop a new mouse model of human glaucoma, which will allow a better understanding of the disease process and provide an appropriate model to test new glaucoma therapies.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21EY019977-02
Application #
8018064
Study Section
Anterior Eye Disease Study Section (AED)
Program Officer
Araj, Houmam H
Project Start
2010-02-01
Project End
2012-09-30
Budget Start
2011-02-01
Budget End
2012-09-30
Support Year
2
Fiscal Year
2011
Total Cost
$174,000
Indirect Cost
Name
University of North Texas
Department
Anatomy/Cell Biology
Type
Other Domestic Higher Education
DUNS #
110091808
City
Fort Worth
State
TX
Country
United States
Zip Code
76107
O'Brien, Colm; Clark, Abbot F (2016) Introduction to EER Special Issue on ocular fibrosis. Exp Eye Res 142:1
Stamer, W Daniel; Clark, Abbot F (2016) The many faces of the trabecular meshwork cell. Exp Eye Res :
McDowell, Colleen M; Hernandez, Humberto; Mao, Weiming et al. (2015) Gremlin Induces Ocular Hypertension in Mice Through Smad3-Dependent Signaling. Invest Ophthalmol Vis Sci 56:5485-92
Pang, Iok-Hou; Millar, J Cameron; Clark, Abbot F (2015) Elevation of intraocular pressure in rodents using viral vectors targeting the trabecular meshwork. Exp Eye Res 141:33-41
McDowell, Colleen M; Tebow, Holly E; Wordinger, Robert J et al. (2013) Smad3 is necessary for transforming growth factor-beta2 induced ocular hypertension in mice. Exp Eye Res 116:419-23
McDowell, Colleen M; Luan, Tomi; Zhang, Zhang et al. (2012) Mutant human myocilin induces strain specific differences in ocular hypertension and optic nerve damage in mice. Exp Eye Res 100:65-72